Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer

Tanta University

Status: Unknown

Conditions: Thrombosis

Treatments: Diagnostic Test: Genetic Mutations

Study type: Interventional

Funder types: Other

Identifiers

NCT03180567

Prof Amr gawaly

Details and patient eligibility

About

As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of bleeding) or a low INR (with a risk of thrombosis)

Full description

The results of this project will benefit in (1) Identification of novel features or mutation types in warfarin resistance genomes. (2) To determine whether other polymorphisms in noncoding regions or their unique haplotype combinations contribute to the variability in the maintenance dose of warfarin, and (3)personalization of the drug and deciding the correct dose from the start.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with thrombosis and warfarin resistance

Exclusion criteria

• less than 18 years

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups, including a placebo group

Warfarin resistant patients

Experimental group

Description:

Genetic Mutations

Treatment:

Diagnostic Test: Genetic Mutations

Control

Placebo Comparator group

Description:

Genetic Mutations

Treatment:

Diagnostic Test: Genetic Mutations